文献速递中毒与环境急症重症综合管理与镇静镇痛

氯氮卓治疗酒精戒断症状后入住ICU或高依赖病房患者的前瞻性药代动力学研究

A prospective pharmacokinetic study of chlordiazepoxide in patients admitted to an intensive care unit or a high dependency unit after treatment of alcohol withdrawal symptoms.
PubMed 文献 · Clin Toxicol (Phila) · 2026-03-04
一句话结论氯氮卓剂量与血药浓度相关性差(r²=0.35),且激动组浓度高于镇静组,作者认为治疗药物监测不适用于指导氯氮卓治疗。

这项前瞻性临床队列研究纳入26例因酒精戒断症状接受氯氮卓≥200 mg方案化治疗后入住ICU或高依赖病房的患者,按临床状态分为镇静组(19例,呼吸功能不全或嗜睡)和激动组(7例,尽管使用苯二氮卓类仍有戒断症状)。入组时85%患者血浆氯氮卓浓度高于3.5 mg/L。激动组中位累积剂量为1,350 mg(四分位距900-2,050 mg),高于镇静组的700 mg(四分位距275-1,250 mg);激动组血浆氯氮卓浓度显著高于镇静组(20 mg/L对8.6 mg/L,P=0.002)。剂量与血药浓度相关性差(r²=0.35,P=0.001)。作者认为剂量、血药浓度与临床效应之间相关性差,限制了用累积剂量和血药浓度预测延长镇静和呼吸抑制风险的能力。

要点

  • 26例因酒精戒断接受氯氮卓≥200 mg治疗后入住ICU或高依赖病房的患者中,19例表现为镇静(呼吸功能不全或嗜睡),7例仍激动。
  • 入组时85%患者血浆氯氮卓浓度高于3.5 mg/L。
  • 激动组中位累积剂量1,350 mg(四分位距900-2,050 mg)高于镇静组700 mg(四分位距275-1,250 mg)。
  • 激动组血浆氯氮卓浓度显著高于镇静组(20 mg/L对8.6 mg/L,P=0.002)。
  • 剂量与血浆氯氮卓浓度相关性差(r²=0.35,P=0.001),作者认为治疗药物监测不适用于指导氯氮卓治疗。

适用人群与场景

  • 因酒精戒断症状接受方案化氯氮卓治疗≥200 mg后入住ICU或高依赖病房的患者。

诊断标准与关键阈值

  • 镇静组:呼吸功能不全或嗜睡;激动组:尽管接受苯二氮卓类治疗仍存在酒精戒断症状。

红旗征与不能漏的情况

  • 镇静组表现为呼吸功能不全或嗜睡,需入住ICU或高依赖病房监护。

研究设计与关键结果

  • 前瞻性临床队列研究纳入26例患者,其中19例为镇静组、7例为激动组。
  • 入组时85%患者血浆氯氮卓浓度高于3.5 mg/L。
  • 激动组中位累积剂量1,350 mg(四分位距900-2,050 mg)高于镇静组700 mg(四分位距275-1,250 mg)。
  • 激动组血浆氯氮卓浓度显著高于镇静组(20 mg/L对8.6 mg/L,P=0.002)。
  • 剂量与血浆氯氮卓浓度相关性差(r²=0.35,P=0.001)。

证据类型、等级与局限

  • 证据类型:前瞻性临床队列研究。
  • 作者结论:剂量、血药浓度与临床效应之间相关性差,限制了用累积剂量和血药浓度预测延长镇静和呼吸抑制风险的能力,使氯氮卓在酒精戒断症状治疗中不可靠;作者认为治疗药物监测不适用于指导氯氮卓治疗。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为个体敏感性及其他差异影响临床结局,治疗药物监测不适用于指导氯氮卓治疗。
  • 作者认为剂量、血药浓度与临床效应之间相关性差,氯氮卓在酒精戒断症状治疗中不可靠。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Chlordiazepoxide is used to manage alcohol withdrawal symptoms. Owing to its active metabolites with long half-lives, vulnerable patients may be at increased risk of prolonged sedation and respiratory depression, potentially requiring intensive care. This study aimed to characterize chlordiazepoxide dosing and related plasma concentrations in patients admitted to an intensive care unit or high dependency unit after chlordiazepoxide treatment for alcohol withdrawal symptoms.

METHODS: A prospective clinical cohort study of patients admitted to the intensive care unit or high dependency unit after protocolized treatment with chlordiazepoxide ≥200 mg. Patients were classified as either sedated (respiratory insufficiency or somnolence) or agitated (alcohol withdrawal symptoms despite benzodiazepine treatment). Blood samples were collected at enrolment and 12 h later to measure concentrations of chlordiazepoxide, norchlordiazepoxide, and demoxepam.

RESULTS: Of 26 patients included, 19 patients were sedated, and seven were agitated. At inclusion, 85% had plasma chlordiazepoxide concentrations above 3.5 mg/L. The median cumulative dose was higher in the agitated group (1,350 mg [interquartile range: 900-2,050 mg]) compared to the sedated group (700 mg [interquartile range: 275-1,250 mg]). Plasma chlordiazepoxide concentrations were significantly higher (P = 0.002) in the agitated group compared to the sedated group (20 mg/L versus 8.6 mg/L). Correlation between dose and plasma concentration (r2 = 0.35; P = 0.001) was poor.

DISCUSSION: Agitated patients were treated with higher doses and expectedly had higher chlordiazepoxide plasma concentrations than sedated patients, indicating that individual sensitivity and other differences play a role in clinical outcome, which emphasizes that therapeutic drug monitoring is not suitable for guiding treatment with chlordiazepoxide.

CONCLUSIONS: Poor correlation between doses, plasma concentrations, and clinical effects limits the ability to use cumulated doses and plasma concentrations to predict the risk of prolonged sedation and respiratory depression, making chlordiazepoxide unreliable in the treatment of alcohol withdrawal symptoms.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Reiter N, Dalhoff K, Petersen TS, et al. A prospective pharmacokinetic study of chlordiazepoxide in patients admitted to an intensive care unit or a high dependency unit after treatment of alcohol withdrawal symptoms. Clin Toxicol (Phila). 2026. PMID: 41778414. doi:10.1080/15563650.2026.2630024

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。